Document Detail


Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
MedLine Citation:
PMID:  21340026     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.
Authors:
Romain Coriat; Hervé Gouya; Olivier Mir; Stanislas Ropert; Olivier Vignaux; Stanislas Chaussade; Philippe Sogni; Stanislas Pol; Benoit Blanchet; Paul Legmann; François Goldwasser
Related Documents :
18712606 - Exothermic reaction in zeolite hemostatic dressings: quikclot acs and acs+.
17586576 - Characterization of the threshold response of initiation of blood clotting to stimulus ...
21507166 - Blood transfusion: old blood, new blood or no blood.
7081126 - The relationship between high fibrinolytic activity and daily capsicum ingestion in thais.
8879626 - Target value tailored (tvt) apheresis approach for blood progenitor cell collection aft...
33876 - Favourable effect of storage at 0 degrees c on the o2 transport function of heparinized...
Publication Detail:
Type:  Journal Article     Date:  2011-02-14
Journal Detail:
Title:  PloS one     Volume:  6     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2011  
Date Detail:
Created Date:  2011-02-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e16978     Citation Subset:  IM    
Affiliation:
Center for Research on Angiogenesis Inhibitors (CERIA), Hôpital Cochin, AP-HP, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple...
Next Document:  D-Cbl Binding to Drk Leads to Dose-Dependent Down-Regulation of EGFR Signaling and Increases Recepto...